WO2022234266A1 - Distributing microparticles - Google Patents
Distributing microparticles Download PDFInfo
- Publication number
- WO2022234266A1 WO2022234266A1 PCT/GB2022/051126 GB2022051126W WO2022234266A1 WO 2022234266 A1 WO2022234266 A1 WO 2022234266A1 GB 2022051126 W GB2022051126 W GB 2022051126W WO 2022234266 A1 WO2022234266 A1 WO 2022234266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microparticles
- tumour
- ultrasound
- radioisotope
- insertion site
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title claims abstract description 174
- 238000000034 method Methods 0.000 claims abstract description 123
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 113
- 238000002604 ultrasonography Methods 0.000 claims abstract description 87
- 238000003780 insertion Methods 0.000 claims abstract description 59
- 230000037431 insertion Effects 0.000 claims abstract description 59
- 238000009826 distribution Methods 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 37
- 210000001519 tissue Anatomy 0.000 claims description 62
- 239000004005 microsphere Substances 0.000 claims description 33
- 230000005855 radiation Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 239000002101 nanobubble Substances 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 10
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical group [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 8
- 239000000919 ceramic Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 230000003019 stabilising effect Effects 0.000 claims description 7
- 229940044173 iodine-125 Drugs 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims description 4
- KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- SIXSYDAISGFNSX-BJUDXGSMSA-N scandium-44 Chemical compound [44Sc] SIXSYDAISGFNSX-BJUDXGSMSA-N 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 210000003800 pharynx Anatomy 0.000 claims description 3
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 3
- 239000005354 aluminosilicate glass Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010015866 Extravasation Diseases 0.000 claims 2
- 230000036251 extravasation Effects 0.000 claims 2
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 2
- 102000011990 Sirtuin Human genes 0.000 claims 1
- 108050002485 Sirtuin Proteins 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 238000000339 bright-field microscopy Methods 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 238000005336 cracking Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000004992 fission Effects 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
- 239000007789 gas Substances 0.000 description 34
- 239000000017 hydrogel Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 230000002285 radioactive effect Effects 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 231100000987 absorbed dose Toxicity 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002331 radioactive microsphere Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000000730 radioembolic effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960000909 sulfur hexafluoride Drugs 0.000 description 2
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- NOYHHKBOLBIMAR-UHFFFAOYSA-K 2-(carboxymethyl)-2,4-dihydroxy-4-oxobutanoate;yttrium(3+) Chemical compound [Y+3].OC(=O)CC(O)(C([O-])=O)CC(O)=O.OC(=O)CC(O)(C([O-])=O)CC(O)=O.OC(=O)CC(O)(C([O-])=O)CC(O)=O NOYHHKBOLBIMAR-UHFFFAOYSA-K 0.000 description 1
- 230000005461 Bremsstrahlung Effects 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YZKBALIHPXZPKY-UHFFFAOYSA-N [Mn].[Sr] Chemical compound [Mn].[Sr] YZKBALIHPXZPKY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005249 arterial vasculature Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000005466 cherenkov radiation Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002110 nanocone Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 229960004692 perflenapent Drugs 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-BJUDXGSMSA-N zirconium-90 Chemical compound [90Zr] QCWXUUIWCKQGHC-BJUDXGSMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1007—Arrangements or means for the introduction of sources into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
- A61N2005/1024—Seeds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0039—Ultrasound therapy using microbubbles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0056—Beam shaping elements
- A61N2007/0065—Concave transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0086—Beam steering
- A61N2007/0095—Beam steering by modifying an excitation signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1027—Interstitial radiation therapy
Definitions
- the present invention relates to distributing microparticles, and in some aspects to treatment of a solid tumour by distributing microparticles comprising a radioactive isotope.
- Microparticles such as microspheres are used in many applications. For example they may be used as a diagnostic tool in medical assays, or to alter the density of a plastic to provide extra buoyancy.
- Radioactive microparticles i.e. microparticles comprising at least one radioisotope, can be used for imaging or for manipulation of matter inside a medium. They are used widely in medical imaging and in the diagnosis of various diseases. In many of these uses, positioning microparticles at their intended location can be difficult.
- Radioactive microparticles A particular application of radioactive microparticles is in treatment of tumours.
- Brachytherapy and its modem evolution selective internal radiation therapy (SIRT) involves the implantation of radioactive nuclei either as bulk solids (e.g. Iodine crystals) or as colloidal suspensions (e.g. Yttrium citrate suspension) in a liquid medium.
- SIRT was developed to extend and improve the quality of life of patients with non-resectable hepatocellular carcinomas (HCC), for whom external beam radiotherapy (EBRT) is not suitable due to the liver’s poor tolerance of radiation.
- HCC non-resectable hepatocellular carcinomas
- EBRT external beam radiotherapy
- SIRT short stature isotopes of known grade to localise radiation using permanent biocompatible microspheres, with calculated emission energies and treatment durations, for specific indications.
- SIRT allows for precise, controlled radiotherapy to radiosensitive organs and tissues, which otherwise would not tolerate large dose of unfocused, diffuse radiation.
- Treatment is minimally invasive, via femoral or radial access, enabling delivery through out-patient care and making it an attractive alternative to EBRT.
- adoption and practice of SIRT as a palliative technique did not become widespread until the approval of current SIRT products in the 2000’ s. SIRT remains a non-curative treatment, recommended by several health agencies across the globe.
- the therapeutic effect of SIRT is hampered by the terminal distribution of the radioactive microspheres. Due to the limited depth of radiation penetration produced by beta emission from commercial radioembolics, treatment efficacy is directly correlated with the distribution of the microspheres within the tumorous tissue. Treatment of larger areas requires either a larger number of microspheres or a greater distribution of the same number of spheres, with a decreased intensity of radiation. The distribution of the microspheres is ultimately limited by the placement of the catheter delivering them. In hypoxic solid tumours large areas of the tumour may remain untreated due to the vasculature of the cancer primarily being present on the periphery of the solid lesion, preventing delivery of radioactive microspheres to the centre of the solid mass.
- a method of distributing microparticles comprising: providing a plurality of microparticles at an insertion site in a medium; and applying ultrasound to the insertion site that generates gas bubbles by cavitation at cavitation nuclei located at the insertion site and drives movement of the gas bubbles such that the gas bubbles drive movement of the microparticles into a desired spatial distribution in the medium.
- microscale particles can be driven by bubbles, in particular microbubbles, generated by ultrasound-induced cavitation.
- Ultrasound- induced cavitation of microbubbles has been used to entrain nanoscale particles in a liquid of the medium, but it was unexpected that ultrasound-induced cavitation of microbubbles can also drive movement of much larger (and heavier) microscale particles.
- the mechanism of entraining used in the nanoscale regime would not be possible in the very different size and mass regime of microscale particles.
- gas microbubbles generated by ultrasound-induced cavitation are able to directly impart kinetic energy to microscale particles, and so drive movement of microparticles.
- cavitating refers to the evolution (i.e. growth) and subsequent oscilliation of bubbles, of various sizes, from the cavitation nuclei.
- the bubbles may or may not subsequently collapse during the application of the ultrasound.
- the applied ultrasound performs two functions, namely generating gas bubbles which are suitable for driving the micropartices by cavitation from the cavitation nuclei; and driving movement of the bubbles.
- the cavitating bubbles in turn drive movement of the microparticles, distributing the microparticles into a desired spatial distribution.
- the microbubbles may cause the microparticles to disperse within the medium and/or translate the microparticles within the medium.
- microparticles can be non-invasively spread from their initial location, avoiding the limited distribution of microparticles discussed above, such as where limited capillary size prevents further spread.
- the microspheres may be spread into a tumour even where vasculature is limited towards the centre of the tumour.
- providing the plurality of microparticles at the insertion site may comprise providing the plurality of microparticles at a location where cavitation nuclei are located.
- the cavitation nuclei may be endogenous to the insertion site.
- both microparticles and cavitation nuclei may be provided to the insertion site, either together as a composition or separately.
- the cavitation nuclei from which microbubbles are generated may comprise both endogenous nuclei already at the insertion site, and exogenous nuclei provided to the insertion site.
- exogenous cavitation nuclei may be preferable, as high ultrasound energy may be required to generate bubbles from endogenous cavitation nuclei. This may be due to low numbers of endogenous cavitation nuclei, or inefficiency or a high activation energy when generating bubbles from endogenous cavitation nuclei.
- the high ultrasound energy required for cavitation from endogenous nuclei may damage the surrounding medium.
- the cavitation nuclei may comprise at least one of: microbubbles, nanobubbles, nanodroplets and gas stabilising nanoparticles, such as nanocups or nanocones, i.e. nanoscale gas stabilising shells with a void acting as a cavitation nucleus.
- each microparticle may comprise a radioisotope, such as a beta- or gamma- emitting radioisotope.
- the radioisotope may be one or more of yttrium-90, iodine-125, copper-64, scandium-44, leutitium-176 or holmium-166. It has been found that the ultrasound approach to driving microparticles provides an efficient and effective method for distributing radioactive microparticles in or around a medium.
- the microparticles may comprise a therapeutic agent.
- the therapeutic agent may comprise one or more radioisotopes, as above.
- the medium may be a tissue, such as human tissue.
- the tissue may be in or may have been removed from a patient.
- the tissue may be a tumour or part of a tumour.
- the method may be a method for treating a tumour by distributing microparticles comprising a radioisotope.
- the tumour may be a tumour of the liver, brain, pancreas, kidney, lung, throat, neck or gut, and in particular may be a glioma, a glioblastoma, or a meningioma.
- a method for treating a solid tumour comprising: providing a plurality of microparticles at an insertion site in a tissue of a patient, wherein of the microparticles comprises at least one radioisotope; applying ultrasound to the injection insertion site that generate gas bubbles from cavitation nuclei located at the insertion site, and drives movement of the gas bubbles such that the gas bubbles drive movement of the microparticles into a spatial distribution for providing radiation to treat the tumour.
- the insertion site may be within the tumour, or outside of the tumour, e.g. adjacent to the tumour.
- the spatial distribution may be a distribution through the tumour.
- any embodiment of the first aspect of the invention may be combined with the second aspect, in particular embodiments relating to the nature of the ultrasound, cavitation nuclei, and/or microparticles.
- a third aspect of the invention there is provided a plurality of microparticles, the microparticles comprising a radioisotope, the microparticles being for use in the treatment of a tumour by the method according to any embodiment of the second aspect of the invention or any embodiment of the first aspect wherein the method is a method of treating a solid tumour.
- a fourth aspect of the invention there is provided a plurality of cavitation nuclei, the cavitation nuclei being for use in the treatment of a tumour by the method according to any embodiment of the second aspect of the invention or any embodiment of the first aspect wherein the method is a method of treating a solid tumour.
- a composition comprising a plurality of cavitation nuclei and a plurality of microparticles, the microparticles comprising a radioisotope, for use in the treatment of a tumour by the method according to any embodiment of the second aspect of the invention or any embodiment of the first aspect wherein the method is a method of treating a solid tumour.
- products comprising a plurality of cavitation nuclei and a plurality of microparticles, the microparticles comprising a radioisotope, as a combined preparation for simultaneous, separate, or sequential use in the treatment of a tumour by the method according to any embodiment of the second aspect of the invention or any embodiment of the first aspect wherein the method is a method of treating a solid tumour.
- the cavitation nuclei and the microparticles may be supplied and inserted into the body separately, but are used together by application ultrasound to treat the tumour.
- a seventh aspect of the invention there is provided use of a plurality of microparticles, the microparticles comprising a radioisotope, in the manufacture of a medicament for the treatment of a tumour by the method according to any embodiment of the second aspect of the invention or any embodiment of the first aspect wherein the method is a method of treating a tumour.
- an eighth aspect of the invention there is provided use of a plurality of cavitation nuclei in the manufacture of a medicament for the treatment of a tumour by the method according to any embodiment of the second aspect of the invention or any embodiment of the first aspect wherein the method is a method of treating a tumour.
- a ninth aspect of the invention there is provided use of a composition comprising a plurality of cavitation nuclei and a plurality of microparticles, the microparticles comprising a radioisotope, in the manufacture of a medicament for the treatment of a tumour by the method according to any embodiment of the second aspect of the invention or any embodiment of the first aspect wherein the method is a method of treating a solid tumour.
- Fig. 1(a) illustrates a method of distributing microparticles according to the present invention
- Fig. 1(b) illustrates a particular example of the first step of the method of Fig. 1(a);
- Fig. 1(c) illustrates a further example of the first step of the method of Fig. 1(a)
- Fig. 2 schematically represents the method of Fig. 1(a) being applied to microparticles
- Fig. 3 illustrates bubble formation using nanocups
- Fig. 4 is a schematic representation of the electronic setup for ultrasound production from a HIFU transducer
- Figs. 5 and 6 shows pCT images to illustrate the effect of focal pressure on microparticle distribution
- Fig. 7 shows pCT images to illustrate the effect of well diameter on microparticle distribution
- Fig. 8 shows pCT images to illustrate the effect of duty cycle on microparticle distribution.
- Fig. 1(a) illustrates a method of distributing microparticles using ultrasound according to the present invention. As discussed above, it can be difficult to move microparticles to their intended position in a medium. Microparticles may cluster at an insertion site rather than move to a desired distribution, particularly where capillaries are used to introduce microparticles to a medium. The method of Fig. 1(a) improves the distribution of microparticles by applying ultrasound energy.
- the method of Fig. 1(a) is used to distribute particles in a medium.
- the medium may be a material, such as a plastic, in which the microparticles are used to alter a material property such as density or buoyancy or for diagnostic purposes, for example to act as externally detectable radioactive tracers.
- the medium may be a tissue, such as a human tissue.
- the tissue may be in vivo or ex vivo.
- the microparticles may be used in the tissue for diagnostic purposes (e.g. radioactive tracers) or non-diagnostic and non-treatment purposes (such as altering characteristics of the tissue).
- the microparticles may alternatively or additionally be used in the tissue for treating a disease.
- the method may be used to distribute particles into a spatial distribution for treating a tumour.
- the tumour may be a solid tumour.
- the method may be a method of treating a tumour by distributing microparticles, each microparticle comprising a therapeutic agent such as a radioisotope.
- the method may be used to provide selective internal radiation therapy (SIRT).
- SIRT selective internal radiation therapy
- SIRT has been used to treat a variety of tumour types although it is most commonly used to treat liver cancers such as hepatocellular carcinoma (HCC), cholangiocarcinoma and metastases of colorectal cancer (mCRC) in the liver .
- Other examples of SIRT treatment include pancreatic neuroendocrine tumours (pNETs), lung tumours and CNS tumours such as gliomas.
- pNETs pancreatic neuroendocrine tumours
- lung tumours and CNS tumours
- gliomas such as gliomas.
- glioblastoma is the second most frequently reported brain tumour, after meningioma, and the most common malignant tumour.
- Glioblastoma accounts for 15.4% of all primary brain tumours and 45.6% of primary malignant brain tumours in the United States.
- Patients with glioblastoma multiforme (GBM) have mean survival of 1 year with only 5% of individuals living for 5 or more years, with no prevention strategy or standardised second-line treatment available; these distressing figures are reflective of the limited treatments available, with most procedures resulting in reoccurrence and disease progression from 10 to 30 weeks.
- the method of Fig. 1(a) may be used in the treatment of glioblastoma, as well as glioma and meningioma. In general, the method may be used to treat solid tumours of the liver, brain, pancreas, kidney, lung, throat, neck or gut.
- the method of Fig. 1(a) begins at step 101, at which a plurality of microparticles are provided at an insertion site in the medium.
- the insertion site is also provided with, or already comprises, cavitation nuclei, as discussed in more detail below in relation to Figs. 1(b) and 1(c).
- Providing the microparticles may comprise injecting or otherwise inserting a plurality of microparticles at a common location. Where the microparticles are introduced via a capillary or cavity, either naturally occurring or fabricated, the insertion site may be separate from the point at which microparticles are initially introduced into the capillary. For example, the insertion site may be at the end of a capillary.
- providing may comprise providing a plurality of microparticles at an insertion site in a tissue of a patient.
- the tissue may be the tumour itself, or a tumour remnant (following incomplete excision) or tissue adjacent to or surrounding the tumour or remnant.
- Figs. 2(a) and 2(b) show a schematic example of the method of Fig. 1(a).
- Fig. 2(a) shows a medium 201 in which microparticles will be distributed.
- a plurality of microparticles 203 are inserted into a cavity 202, where they gather at an insertion site 204.
- the microparticles 203 are subsequently distributed in the medium 201 by application of ultrasound from an ultrasound transducer 205, as will be discussed in more detail below in relation to step 102 of the method of Fig. 1(a).
- the microparticles may be microspheres.
- a microsphere is a micron scale particle, which may be either solid or hollow, and which is approximately spherical.
- the microparticles may comprise or consist of a ceramic.
- Such ceramics may comprise a radioisotope, such as yttrium-90 and one or more additional elements such as silicon, aluminium, gallium, strontium manganese or titanium. Since the starting materials are typically be in the form of salts such as oxides or carbonates the ceramic will typically also comprise oxygen. In one approach the ceramic may be a yttrium aluminosilicate glass. Ceramic materials may be particularly useful for providing inert, relatively incompressible microparticles.
- TheraSphere ® microspheres are a combination of three high purity metal oxides, yttrium, aluminium and silicon which are blended and melted together at extreme temperatures to produce a solid (YAS) glass.
- the glass is shattered, powdered and spheriodised over a naked flame to form the YAS microspheres (see for example US4789501, which is incorporated herein by reference).
- Further examples of ceramic SIRT microspheres are described in WO 16082045 and WO05087274).
- microparticles which are particles with a size (which may be a diameter) in a range from 1 p to 1000 pm.
- the microparticles may have an average size of 200 pm or less, or preferably 150 pm or less, or more preferably 120 pm or less.
- the microparticles may have a minimum size of 1 pm or more, or preferably 5 pm or more, or more preferably 10 pm or more, or 20 pm or more, or 50 pm or more, or 100 pm or more.
- the TheraSphere ® microspheres have a size range of 15-35 pm, with a mean size in the range 20-30pm, which is well- suited to both the present method and to placement in human tissue.
- the microparticle sizes may be determined by scanning electron microscopy (SEM), optical microscopy, and/or laser diffraction particle size analysis.
- the microparticles may comprise at least one radioisotope.
- the radioisotope may a beta- or gamma- emitting radioisotope, such as Yttrium-90, Iodine- 125, Copper-64, Scandium-44, leutitium-176 or Holmium-166.
- isotope selection is screened against energy emission (electron volts, eV) and efficacy weighed against the systemic toxicity of the radioactive isotope decay product.
- Iodine- 125 and Yttrium-90 are of particular use, due to the poor biological availability of Iodine-125 over Iodine-127 and the inert decay product of Yttrium-90, Zirconium-90.
- beta-emitting isotopes e.g. Cu-64, Sc-44, Lu-176, Ho-166
- SPECT single photon emission computed tomography
- MRI magnetic resonance imaging
- YAS microspheres comprising Y 89 are subjected to neutron bombardment in a nuclear reactor, producing Yttrium-90 as the sole radioactive component.
- Other isotopes formed as the result of the neutron bombardment of silicon or aluminium are deemed stable or insignificant by composition.
- the enriched Y 90 isotope undergoes b decay to Zr 90 with a half-life of 64. lh and a decay energy of 0.93 MeV mean energy.
- Emissions of electrons from the unstable Y 90 atoms are decelerated by neighbouring atoms electrostatic repulsions; this deceleration and loss of kinetic energy is emitted as ‘braking’ gamma radiation to the surrounding cells (Bremsstrahlung or Cerenkov radiation) and can be detected externally for imaging.
- the energy emitted into neighbouring cells causes DNA double strand breaks, with downstream signalling of this DNA damage inducing cellular necrosis.
- the microparticles may be selected to have a radioactive activity level suitable for providing a clinically acceptable absorbed dose of radiation for the intended treatment.
- TheraSphere ® has an activity per microsphere at calibration of 2500Bq.
- the microparticles may have an activity of at least 10 Bq, preferably at least 40Bq.
- the activity is at least 500, preferably at least 100 and most preferably at least 2000Bq per sphere.
- Maximal activity per sphere is determined by factors such as the selected isotope, number of spheres to be delivered etc. In some embodiments the maximum may be 3000Bq preferably 5000 Bq, to provide optimum treatment whist minimising damage to surrounding healthy tissue.
- Total activity of a dose of microspheres may be in the range 3GBq to 20GBq.
- the target for tumour absorbed dose depends on the susceptibility of the tumour tissue and the surrounding healthy tissue to radiation.
- An absorbed dose to tumour tissue of at least 50Gy is desirable, but preferably at least 150Gy.
- the doses used for liver tumours may be between 50 and 500 Gy, typically at least 150Gy and preferably at least 200Gy.
- the LEGACY study has recently suggested that doses of at least 400Gy provide a high level of response in liver tumours such as HCC (Ann Oncol. 2020;31(suppl 4):S692-S693).
- CNS tumours such as glioma a dose of between 35Gy and 115Gy has been reported (Pasciak et al EJNMMI Res.
- the microparticles may have a density of 10 g/ml or less, or preferably 5g/ml or less, or more preferably 4g/ml or less.
- the microparticles may have a density of lg/ml or more, or preferably 2g/ml or more, or more preferably 3g/ml or more.
- TheraSphere ® ’microparticles have a relative density of 3.6 gml 1 .
- These comparatively high densities result from using substantially incompressible materials, which is desirable for SIRT and other application of microspheres.
- the combination of high density and micron size particles results in relatively heavy particles, at least as compared to the nanoparticle regime.
- density is the density of an individual microparticle. Density may be determined from the crude material of which the microparticles are formed (e.g. glass) prior to spheroidising.
- the insertion site may be within the tumour.
- the insertion site may be adjacent to the tumour, for example at a distance sufficiently close to the tumour that the ultrasound energy discussed in step 102 below is able to drive movement of microparticles into the tumour.
- the insertion site may be on the surface of the tumour, or within 5 cm, or within 2 cm, or with 1 cm of the surface of the tumour.
- the insertion site may be within a cavity or capillary formed by excising a portion of the tumour.
- the method of Fig. 1(a) may comprise excising a portion of the tumour to form the cavity.
- the insertion site may be at a tumour margin formed by excising a portion of the tumour.
- the method of Fig. 1(a) may comprise excising a portion of the tumour to form the tumour margin or tumour remnant
- Delivery of the microparticles may be performed with sterile 0.9% saline, flushing the spheres out of their v-glass vial residing within a secondary acrylic holder, into the arterial vasculature via microcatheter.
- the placement of the tip and the internal diameter of the microcatheter is determined by the operator, availability and territory preferences. Delivery may be carried out by catheter to a point in the vasculature that serves the general volume of tissue, rather than the tumour itself. This process relies on the tumour co-opting the local blood supply so that in fact the majority of the microparticles ends up in the tumour, although some percentage still go to the surrounding tissue.
- microparticles may be delivered directly to the blood vessel feeding the tumour.
- This may be referred to as super selective delivery, as almost all of the microparticles go into the tumour and only limited amounts go to surrounding tissues. Completion of the irradiation treatment occurs within 2 weeks, with patient follow up occurring after 6 weeks; consisting of further imaging of the parenchyma and necrotic tissue, potentially with further histology to assess procedural performance.
- the microparticles 203 are provided at the insertion site 204 where cavitation nuclei are located.
- a cavitation nucleus can be considered as any material that under exposure to ultrasound, produces an expanding bubble of gas that undergoes either inertial (collapse) or non-inertial cavitation.
- the expanded bubbles may have at diameter, at maximal extent, in the range 1 p to 500pm.
- the generated bubbles may be termed microbubbles.
- the size of a bubble may oscillate in accordance with the frequency of the applied ultrasound field.
- the density of the expanded bubbles will generally be much lower than the density of the microspheres.
- the density (or mean density) of the expanded bubbles may be in the range 0.5 kg/m 3 to 2 kg/m 3 , or in the range 0.9 kg/m 3 to 1.1 kg/m 3 .
- exogenous cavitation nuclei are provided at the insertion site 204.
- step 101 comprises providing a composition of both microparticles 203 and cavitation nuclei to the insertion site 204.
- Figs. 1(b) and 1(c) illustrate two alternative embodiments to using a combined composition, in which the cavitation nuclei and microparticles 203 are provided in separate steps.
- step 101 comprises a first step 1001 of providing microparticles 203 at the insertion site 204, for example using the insertion methods discussed above. After inserting the microparticles 204, the method proceeds to step 1002, at which cavitation nuclei are provided to the insertion site 204.
- the process of providing the cavitation nuclei may be substantially similar to the processes of inserting microparticles discussed above.
- step 101 of the method comprises a first step 1101 of providing cavitation nuclei at the insertion site 204.
- step 1102 microparticles 203 are provided at the insertion site 204.
- the insertion site 204 to which the plurality of microparticles are provided in step 101 may be a location where cavitation nuclei are already located.
- the cavitation nuclei may be endogenous to the insertion site. In such embodiments, there may be no step of providing exogenous cavitation nuclei.
- exogenous cavitation nuclei may be provided to a site that already has endogenous cavitation nuclei, to enhance the cavitation effect.
- exogenous cavitation nuclei are preferred, as they tend to require less ultrasound energy to generate the gas bubble. The risk of damage to surrounding tissue caused by the ultrasound is therefore reduced.
- Suitable cavitation nuclei include microbubbles, nanobubbles, gas stabilising nanoparticles (e.g. nanocups), and nanodroplets. Each of these is discussed in more detail below.
- Such cavitation nuclei have been used in combination with ultrasound for nanoscale applications such as drug delivery. These nanoscale particles are on a very different scale to the microparticles of the present invention, particularly the dense, incompressible microspheres used in SIRT.
- the present inventors have found that, surprisingly, these cavitation nuclei and the bubbles they generate can be applied to the much larger and more massive regime of microparticles, and so help overcome the limited distribution of microparticles in SIRT and other microparticle applications.
- the cavitation nuclei may be or comprise microbubbles (MB) and/or nanobubbles.
- Microbubbles and nanobubbles are very small pockets of gas, usually containing a perfluorocarbon gas core coated with phospholipids. Under exposure to ultrasound, these gas pockets expand, increasing the diameter bubble.
- generating bubbles by cavitation at the cavitation nuclei comprises growing/evolving the micro/nanobubbles into larger bubbles suitable for driving the microparticles.
- Microbubbles have been confirmed occurring naturally in vivo, in swine kidneys and porcine liver and observance of microbubbles are linearly proportional to the concentration of human red blood cells (RBC) in vitro.
- RBC red blood cells
- gas filled MB’s When exposed to an external ultrasound field, gas filled MB’s will expand and contract with an amplitude dependent upon the energy and frequency of the field. At low amplitudes the oscillations of bubbles are largely linear but as the amplitude increases the behaviour of the bubble is increasingly non-linear whereby the radial expansion and contraction may vary significantly with the maximum volume of the MB dependent upon the wave pressure.
- the bubble resonance frequency exceeds the ultrasound frequency, the bubbles collapse with the loss of the periodic oscillation denoted as inertial, unstable or transient cavitation. This unstable cavitation event can produce new smaller MBs (nuclei) which have different critical excitation pressures and oscillation frequencies.
- Synthetic microbubbles primarily consist of a gas core, often perfluorocarbon, stabilised by a lipid or protein shell to prevent the dissolution of gas from larger bubbles (>lpm) into the surrounding solution; with stabilised bubbles less than 1 p termed ‘nanobubblesk With the of core-shell chemistry influencing the stability and cavitation threshold of the microbubble population, often with substrates of interest (cytotoxins, metal particles, proteins, viruses) bound to the surface.
- substrates of interest cytotoxins, metal particles, proteins, viruses
- the cavitation nuclei may be or comprise gas stabilising nanoparticles, in the form of cups or cones.
- a nanocup is a nanoscale gas stabilising polymer-based cavitation nucleus.
- Nanocups can be considered an improvement over microbubbles alone.
- One of the largest drawbacks of microbubbles is their inability to cross membranes due to their relative size (>1 pm) compared to that of cellular endothelial pores (100-800nm), with eukaryotic cells typically being in the range of 5-10 pm.
- cavitation events with synthetic microbubbles typically cannot be sustained for more than one to two minutes.
- the use of nanocups however, can result in a fourfold increase in the duration of sustained cavitation.
- Nanometer sized ( ⁇ 1 pm) hollow polymer spheres can be prepared via seeded thermally initiated emulsion polymerisation. As the organic monomers react together, a polymer shell or lens is produced on the surface of the suspended droplets. Due to the osmotic pressure on the unsupported polymer film, the surface shell collapses inwards, producing a polymer disc or ‘ nanocup ⁇ Changing the monomer composition changes the viscosity within the particle during polymerisation and the subsequent size of the cavity produced within the nanocup.
- Fig. 3 schematically illustrates the process of bubble formation from a nanocup
- the small cavity of the concave polymer nanocup 301 has a nanobubble entrapped on its surface 302 the nucleation sites for cavitation events.
- the gas nanobubble 302 expands radially and outside of the cavity in which it is situated under exposure to ultrasound.
- nanobubble 302 reaches a critical size, where the contact angle between the bubble and the nanocup 301 approaches its maxima, and the nanobubble 302 will dissociate itself from the nanocup 301 (at this point the free nanobubble 302 is likely micron sized and can be thought of as a microbubble).
- the nanobubble/microbubble 302 continues to expand. Eventually the full bubble 303 is formed.
- the maximum radius the bubble 303 is independent of the nanocup cavity or acoustic pressure but is directly related to frequency of the focused ultrasound wave.
- the ultrasound amplitude governs the number of bubbles nucleated and consequently the frequency of non-spherical collapse. Further details of bubble formation from nanocups may be found in Kwan, J. J. et al ., “Ultrahigh- Speed Dynamics of Micrometer-Scale Inertial Cavitation from Nanoparticles.” Phys. Rev. Appl. 6, 1-8 (2016), which is incorporated herein by reference.
- Nanodroplets Unlike microbubbles which have a stabilised gas core, nanodroplets have a liquid (e.g.Perfluoropentane, perfluorohexane) perfluorocabon liquid core which is stabilised by similar lipid or phospholipid molecules on the surface. Nanodroplets offer advantages over microbubbles and nanocups, notably having increased stability, particularly in circulation in vivo , compared to that of their gas counterparts. Upon exposure to ultrasound, the highly volatile liquid is vaporised into a gas, generating a bubble. The energy required for this phase transformation however is far higher energy compared to that of gas core cavitation agents, but still remains a viable option for sensitive therapeutic delivery applications. Applying ultrasound
- step 102 ultrasound is applied to the insertion site 204 to generate bubbles by cavitation at cavitation nuclei located at the insertion site.
- the applied ultrasound field drives movement of the generated gas bubbles and clouds thereof such that the gas bubbles drive movement of the microparticles into a desired spatial distribution in the medium.
- the applied ultrasound may cause cavitation of exogenous cavitation nuclei or native cavitation nuclei within the insertion location.
- the applied ultrasound performs two functions. It firstly generates bubbles by cavitation at the cavitation nuclei, as discussed above in relation to step 101. It also drives movement of these generated gas bubbles via the acoustic radiation force acting upon them. The cavitating gas bubbles in turn impart kinetic energy to the microparticles, causing the microparticles to move into the desired spatial distribution.
- the microparticles may disperse and/or translate from their locations at the insertion site. The direction and strength of the ultrasound may be selected to provide a particular movement of the microparticles.
- FIGs. 2(a) and 2(b) An example of this process is illustrated in Figs. 2(a) and 2(b).
- an ultrasound generator 205 generates a beam of ultrasound focussed on the insertion site 204. This utilises cavitation nuclei at the insertion site 204 (for clarity the bubbles and cavitation nuclei are not illustrated in the figure).
- the bubbles drive movement of the microparticles 203, in this case causing them to move into the medium 201 and spread out, yielding a desired spatial distribution of microparticles in the medium 201.
- desired spatial distribution is used herein to refer to a general distribution pattern of the microparticles (e.g. spread out relative to the initial insertion site). The desired spatial distribution depends on the intended use of the microparticles.
- microparticles It has been found that the combination of ultrasound applied to a site with cavitation nuclei and microparticles is able to distribute microparticle far further and more effectively than conventional methods of inserting microparticles.
- the maximum displacement of microparticles from the insertion site resulting from this method may be in the range from 1mm to 4 cm, allowing the microparticles to reach further into tumours than is possible in conventional SIRT methods.
- the microbubbles may drive movement of the microparticles into a spatial distribution for providing radiation to treat the tumour. This may comprise driving the microparticles into the tumour (where the insertion site is in tissue surrounding the tumour) and/or through the tumour.
- the resulting spatial distribution can penetrate further into the tumour than previously possible, and may be more dispersed within the tumour than would otherwise be possible, greatly increasing the amount of the tumour that can be reached and treated. As a result, a much more effective treatment is possible.
- Ultrasound is broadly defined as any frequency above the audible range of humans (20 kHz).
- ultrasound waves are most commonly generated using piezoelectric (PZT) ceramics; with the displacement of the elements shape producing an acoustic wave as a series of compressions and decompressions from the transducer surface.
- PZT piezoelectric
- the waves will expand as a series of concentric concave wave fronts (a single wavelength apart), undulating in velocity as the wave travels through matter; producing bands of high and low pressure as result.
- the intensity of sound is relative to the acoustic impedance of the material, viscosity and its elastic behaviour (Young’s modulus; elastic or visoelastic).
- the particles can either move in the direction of the wave (longitudinal or compressional waves) or orthogonal to the wave (transverse or shear waves).
- the ultrasound wave passes through the tissue or medium, energy is lost either through scattering or heat deposition; with the effective range of the ultrasound constrained by the energy input.
- the amplitude of the wave slowly dissipates inversely to the propagation distance.
- HIFU High intensity focussed ultrasound
- the applied ultrasound is focussed ultrasound, with the focus arranged to be at or near the insertion site.
- the applied ultrasound is high intensity focussed ultrasound (HIFU).
- HIFU is achieved by placing a low-velocity confocal lens at the boundary of the PZT element generating the ultrasound, narrowing the wave front to a single controlled focal point at a fixed distance from the flat element, determined by the curvature of the lens.
- the lens acts by increasing the impedance for the rate of propagation for waves towards the centre of the element, allowing wave fronts (compressions and decompressions) at the edge of the transducer to arrive simultaneously to those at the middle; thus increasing the amplitude of the signal produced at the focal point without increasing the voltage applied to the transducer.
- the focal point far field
- the wave fronts diverge and the signal intensity is lost, with increasing distance.
- ALF acoustic radiation force
- Equation 1 Acoustic radiation force on an object F force in (kgs 2 cm 2 )
- Tissue coagulation the combination of protein denaturation and permanent cell damage, is induced at 43°C in vivo.
- Thermal ablation is correlated to the thermal dose, over 43 °C, for a given period of time; with the thermal dose required for ablation varying in tissues and between species.
- the overall thermotolerance of the brain is particularly low, with each region having its own discrete threshold for damage. Thermal stress is hampered by convection to the surrounding sites; via blood circulation, an increase in cell permeability and perfusion between tissues resulting in a less selective procedure compared to mechanical stress.
- Pre-focal tissue despite receiving ultrasound of lower intensity compared to the focal region, does experience pre-focal energy deposition and heating.
- Pre-focal heating is an important concern for in vivo therapies involving the use of HIFU, where undesired collateral damage can cause thermal ablation prior to the focal point, resulting in skin bums due to the prefocal tissue being continuously exposed to converging HIFU wavefronts.
- the applied ultrasound in the present method may exert a peak negative focal pressure in the range of 1 to 20MPa at the insertion site.
- Fig. 4 illustrates an example of an ultrasound setup 205 that may be used to perform step 102 of the method of Fig. 1(a).
- a transducer 401 may be configured to generate ultrasound with parameters selected by a waveform generator 404 to provide the desired distribution of microparticles. The parameters may be selected to promote the cavitation of bubbles from cavitation nuclei, and desired movement of microbubbles, in order to provide the desired distribution of microparticles.
- the transducer 401 may generate ultrasound with a fundamental frequency in the range from 0.1 to 5MHz.
- the generated ultrasound may have a pulse repetition frequency of in the range from 0.1 to 10Hz.
- the generated ultrasound may have a duty cycle of in the range from 1% to 100% (continuous wave).
- Such parameters have been found to be particularly effective at yielding the desired movement of microparticles, especially in tumour-like media.
- the ultrasound generator 205 of figure 4 comprises a HIFU transducer 401 with its impedance matching network 402, which is driven by the voltage output of the amplifier 403.
- the output voltage of the amplifier 403 is monitored by an oscilloscope 406 using a 1MW high impedance cable 405 to check that there are no anomalies in the transducer drive signal.
- the input voltage and other ultrasound parameters are controlled by the arbitrary waveform generator 404.
- a linear array 407 is inserted concentrically within the HIFU transducer 401 (represented by the dashed lines within transducer 408).
- the linear array 407 is used for real time passive acoustic mapping and post exposure imaging, operated by an imaging controller box 408.
- the imaging controller box 408 is connected to the waveform generator 404 to ensure that the transmit and receive signals are synchronised.
- ultrasound imaging may be used to identify the region to which HIFU pulses should be applied.
- identifying the imaging focus allows the HIFU target focal point to be identified.
- an ultrasound probe may be inserted directly into a post-surgical tissue cavity.
- the transducer was adjusted in 0.1mm increments until the maximum amplitude of the received signal was observed on the oscilloscope. After which a B-mode image was captured (using a Verasonics® system as the image controller 408) Subsequent wells in the same medium were aligned using the x,y coordinates of the b-mode image, visually confirmed before proceeding with ultrasound exposure. After initial alignment the pulse receiver was replaced with a waveform generator. In this instance the pulse repetition frequency or interval (PRF) was dictated by the Verasonics® instrument and the remaining parameters via the waveform generator.
- PRF pulse repetition frequency or interval
- hydrogels have been used as in vitro surrogates for mammalian tissue for decades, for ultrasound imaging; with the speed of sound, acoustic attenuation and acoustic impedance analogous to that of serval cancerous indications. Subtle changes can be made to hydrogel compositions to replicate tissue hardness, porosity, acoustic properties as well as cell structure and environment. As a result, hydrogels can simulate a wide variety of properties found in vivo.
- hydrogels are largely comprised of water, despite being modelled and tested as solids; their solid content is analogous to many animal tissues, satisfying the requirements for speed of sound (about 1540 m s 1 ), attenuation (about 0.5 dB cm 1 MHz 1 ) and backscatter coefficient (in the range from 10 5 to 10 2 , between 2 and 7MHz).
- Hydrogels are therefore a compromise, allowing simulation of the intended investigated material properties akin to their cellular counterpart; hydrogels are not flawless in their design however and replicating one in vivo characteristic, often comes at the expense of another material property due to the complexity of imitating cell structure e.g. replicating the stiffness of a material to simulate a tissue, will frequently compromise the materials permeability.
- hydrogels have a microstructure that varies significantly from that of tissue; having isolated pockets of fluid which redistribute over time under stress within the polymer network Whilst particularly convenient for imitating the material properties of tissues, the fabrication and subsequent consistency of gel models produced are innately variable because of their heterogeneous material properties.
- gel tissue mimics continue to remain the most suitable surrogate for simulating tissue, due to the efficacy of ex vivo tissue 75 .
- Agar based hydrogel was used as the tissue mimic.
- Agar gels are clear, well documented, less variable and considerably faster to produce compared to PVA freeze-thaw hydrogels.
- Agar (3kDa Mw, Sigma Aldrich) was added to deionised water (10pm, MiliQ®, Type 1) at either 0.5 or 1% w/v, degassed under vacuum for a minimum of 2 hours, before heating the suspension to >85°C under microwave irradiation before pouring into the phantom mould and allowing to cool at 4°C for a minimum of 12 hours. Parameter variations and experimental results discussed henceforth are based on 0.5% agar gels.
- Nanocups (from Oxsonics®) and Sonovue (Bracco®) were selected as the cavitation agent for the majority of the experiments. SonoVue® was reconstituted and used as instructed by the manufacturer, in the supplied 1-5 xlO 8 parti clesmL 1 concentration. Nanocups were used in a 1:9 dilution (1.0 x 10 9 particlesmL 1 ), diluting the provided suspension with degassed, filtered deionised water to match the SonoVue® concentration. Both cavitation agents were used in equal volume.
- the pulse repetition frequency was set at 3.3Hz; this was to allow for equivalent duty cycles over various frequencies investigated, limited by the 50,000 cycle burst of the waveform generator.
- Each test well was subjected to a total of 3 million cycles, adjusting the ultrasound exposure time and the number of cycles per ultrasound burst as required.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023568113A JP2024516453A (en) | 2021-05-05 | 2022-05-04 | Microparticle Distribution |
CN202280047576.6A CN117677406A (en) | 2021-05-05 | 2022-05-04 | Distributing particles |
EP22724122.1A EP4333978A1 (en) | 2021-05-05 | 2022-05-04 | Distributing microparticles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2106412.6A GB202106412D0 (en) | 2021-05-05 | 2021-05-05 | Distributing microparticles |
GB2106412.6 | 2021-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022234266A1 true WO2022234266A1 (en) | 2022-11-10 |
Family
ID=76300972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/051126 WO2022234266A1 (en) | 2021-05-05 | 2022-05-04 | Distributing microparticles |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4333978A1 (en) |
JP (1) | JP2024516453A (en) |
CN (1) | CN117677406A (en) |
GB (1) | GB202106412D0 (en) |
WO (1) | WO2022234266A1 (en) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789501A (en) | 1984-11-19 | 1988-12-06 | The Curators Of The University Of Missouri | Glass microspheres |
US5380411A (en) * | 1987-12-02 | 1995-01-10 | Schering Aktiengesellschaft | Ultrasound or shock wave work process and preparation for carrying out same |
WO2000002590A1 (en) * | 1998-07-09 | 2000-01-20 | The Board Of Regents Of The University Of Texas System | Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
US20020138037A1 (en) * | 2001-01-29 | 2002-09-26 | Weimann Ludwig J. | Method and apparatus for intradermal incorporation of microparticles containing encapsulated drugs using low frequency ultrasound |
WO2005087274A1 (en) | 2004-03-05 | 2005-09-22 | Xl Sci-Tech, Inc. | Particulate materials and compositions for radio therapy |
US20060058708A1 (en) * | 2003-12-24 | 2006-03-16 | Gill Heart | Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue |
US20080237028A1 (en) * | 2006-09-05 | 2008-10-02 | Hanoch Kislev | Nucleation in liquid, methods of use thereof and methods of generation thereof |
US20080269668A1 (en) * | 2006-10-27 | 2008-10-30 | Keenan James A | Medical Microbubble Generation |
US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
US20140046181A1 (en) * | 2011-01-05 | 2014-02-13 | The Regents Of The University Of California | Acoustically responsive particles with decreased cavitation threshold |
US20160008497A1 (en) * | 2014-07-09 | 2016-01-14 | Sirtex Medical Limited | Method for Treating Lung Carcinoma |
WO2016082045A1 (en) | 2014-11-26 | 2016-06-02 | Abk Biomedical Inc. | Radioembolic particles |
US20180104455A1 (en) * | 2015-03-26 | 2018-04-19 | Vensica Medical Ltd. | Ultrasonic urinary bladder drug delivery |
US20190175766A1 (en) * | 2016-06-02 | 2019-06-13 | Case Western Reserve University | Stabilized crosslinked nanobubbles for diagnostic and therapeutic applications |
US20200023073A1 (en) * | 2016-09-29 | 2020-01-23 | Sintef Tto As | A new drug delivery system for treatment of disease |
-
2021
- 2021-05-05 GB GBGB2106412.6A patent/GB202106412D0/en not_active Ceased
-
2022
- 2022-05-04 JP JP2023568113A patent/JP2024516453A/en active Pending
- 2022-05-04 EP EP22724122.1A patent/EP4333978A1/en active Pending
- 2022-05-04 CN CN202280047576.6A patent/CN117677406A/en active Pending
- 2022-05-04 WO PCT/GB2022/051126 patent/WO2022234266A1/en active Application Filing
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789501A (en) | 1984-11-19 | 1988-12-06 | The Curators Of The University Of Missouri | Glass microspheres |
US5380411A (en) * | 1987-12-02 | 1995-01-10 | Schering Aktiengesellschaft | Ultrasound or shock wave work process and preparation for carrying out same |
WO2000002590A1 (en) * | 1998-07-09 | 2000-01-20 | The Board Of Regents Of The University Of Texas System | Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
US20020138037A1 (en) * | 2001-01-29 | 2002-09-26 | Weimann Ludwig J. | Method and apparatus for intradermal incorporation of microparticles containing encapsulated drugs using low frequency ultrasound |
US20060058708A1 (en) * | 2003-12-24 | 2006-03-16 | Gill Heart | Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue |
US20150098899A1 (en) * | 2004-03-05 | 2015-04-09 | Xl Sci-Tech, Inc. | Particulate Materials And Compositions For Radio Therapy |
WO2005087274A1 (en) | 2004-03-05 | 2005-09-22 | Xl Sci-Tech, Inc. | Particulate materials and compositions for radio therapy |
US20080237028A1 (en) * | 2006-09-05 | 2008-10-02 | Hanoch Kislev | Nucleation in liquid, methods of use thereof and methods of generation thereof |
US20080269668A1 (en) * | 2006-10-27 | 2008-10-30 | Keenan James A | Medical Microbubble Generation |
US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
US20140046181A1 (en) * | 2011-01-05 | 2014-02-13 | The Regents Of The University Of California | Acoustically responsive particles with decreased cavitation threshold |
US20160008497A1 (en) * | 2014-07-09 | 2016-01-14 | Sirtex Medical Limited | Method for Treating Lung Carcinoma |
US10232063B2 (en) | 2014-07-09 | 2019-03-19 | Sirtex Medical Limited | Method for treating lung carcinoma |
WO2016082045A1 (en) | 2014-11-26 | 2016-06-02 | Abk Biomedical Inc. | Radioembolic particles |
US20180104455A1 (en) * | 2015-03-26 | 2018-04-19 | Vensica Medical Ltd. | Ultrasonic urinary bladder drug delivery |
US20190175766A1 (en) * | 2016-06-02 | 2019-06-13 | Case Western Reserve University | Stabilized crosslinked nanobubbles for diagnostic and therapeutic applications |
US20200023073A1 (en) * | 2016-09-29 | 2020-01-23 | Sintef Tto As | A new drug delivery system for treatment of disease |
Non-Patent Citations (2)
Title |
---|
KWAN, J. J. ET AL.: "Ultrahigh-Speed Dynamics of Micrometer-Scale Inertial Cavitation from Nanoparticles", PHYS. REV., vol. 6, 2016, pages 1 - 8 |
PASCIAK ET AL., EJNMMI RES, vol. 10, 2020, pages 96 |
Also Published As
Publication number | Publication date |
---|---|
EP4333978A1 (en) | 2024-03-13 |
JP2024516453A (en) | 2024-04-15 |
CN117677406A (en) | 2024-03-08 |
GB202106412D0 (en) | 2021-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Choi et al. | Microbubble-size dependence of focused ultrasound-induced blood–brain barrier opening in mice in vivo | |
Izadifar et al. | Mechanical and biological effects of ultrasound: a review of present knowledge | |
Loskutova et al. | Review on acoustic droplet vaporization in ultrasound diagnostics and therapeutics | |
Phenix et al. | High intensity focused ultrasound technology, its scope and applications in therapy and drug delivery | |
Zhang et al. | A continuous tri-phase transition effect for HIFU-mediated intravenous drug delivery | |
Yuh et al. | Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: study in a murine model | |
Maxwell et al. | Disintegration of tissue using high intensity focused ultrasound: Two approaches that utilize shock waves | |
Larina et al. | Optimal drug and gene delivery in cancer cells by ultrasound-induced cavitation | |
Jolesz et al. | Magnetic resonance–guided focused ultrasound: a new technology for clinical neurosciences | |
Pi et al. | Sonodynamic therapy on intracranial glioblastoma xenografts using sinoporphyrin sodium delivered by ultrasound with microbubbles | |
WO2010030819A1 (en) | Systems and methods for opening a tissue | |
Pellow et al. | Breaking free from vascular confinement: status and prospects for submicron ultrasound contrast agents | |
Zhao et al. | Ultrasound technology and biomaterials for precise drug therapy | |
Colen et al. | Future potential of MRI-guided focused ultrasound brain surgery | |
Afadzi et al. | Effect of acoustic radiation force on the distribution of nanoparticles in solid tumors | |
Montoya Mira et al. | Gas-stabilizing sub-100 nm mesoporous silica nanoparticles for ultrasound theranostics | |
Luo et al. | Enhancement of ultrasound contrast agent in high-intensity focused ultrasound ablation | |
Tachibana | Emerging technologies in therapeutic ultrasound: thermal ablation to gene delivery | |
Zhao et al. | Phase‐shift Perfluoropentane Nanoemulsions Enhance Pulsed High‐intensity Focused Ultrasound Ablation in an Isolated Perfused Liver System and Their Potential Value for Cancer Therapy | |
US20220331459A1 (en) | Distributing Microparticles | |
WO2022234266A1 (en) | Distributing microparticles | |
Sasaki et al. | Ultrasound image-guided therapy enhances antitumor effect of cisplatin | |
Xu et al. | Histotripsy: A Method for Mechanical Tissue Ablation with Ultrasound | |
CN115252782A (en) | Oxygen-carrying bionic molecular probe, preparation method thereof and application thereof in HIFU and immune synergistic treatment of cancer | |
Xu et al. | Precision control of lesions by high-intensity focused ultrasound cavitation-based histotripsy through varying pulse duration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22724122 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023568113 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022724122 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022724122 Country of ref document: EP Effective date: 20231205 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280047576.6 Country of ref document: CN |